Related Experiment Video
Updated: Aug 15, 2025
12:45
Robot-assisted Total Mesorectal Excision and Lateral Pelvic Lymph Node Dissection for Locally Advanced Middle-low Rectal Cancer
Published on: February 12, 2022
5.8K
Neoadjuvant radiotherapy for resectable retroperitoneal sarcoma: a meta-analysis.
Xiangji Li1,2, Ruihan Dong3, Mengmeng Xiao1
1Department of Retroperitoneal Tumor Surgery, Peking University International Hospital, 1 Shengmingyuan Road, Changping District, Beijing, People's Republic of China.
Radiation Oncology (London, England)
|December 28, 2022
Summary
Neoadjuvant radiotherapy (NRT) improves outcomes for resectable retroperitoneal sarcoma (RPS) patients. This therapy offers longer overall survival (OS) and recurrence-free survival (RFS) compared to surgery alone.
Area of Science:
- Oncology
- Surgical Oncology
- Radiation Oncology
Background:
- Neoadjuvant radiotherapy (NRT) is feasible for resectable retroperitoneal sarcoma (RPS).
- The clinical benefit of NRT versus surgery alone for RPS remains debated.
Purpose of the Study:
- To systematically evaluate the efficacy of NRT compared to surgery alone for resectable RPS.
- To analyze overall survival (OS), recurrence-free survival (RFS), and local recurrence (LR) rates.
Main Methods:
- Systematic literature search of major databases (PubMed, Embase, etc.).
- Inclusion of randomized controlled trials and cohort studies.
- Meta-analysis of hazard ratios (HRs) for OS, RFS, and LR, with heterogeneity and bias assessment.
Main Results:
- 12 studies with 7778 patients were analyzed.
- NRT demonstrated significant advantages: longer OS (HR=0.81), longer RFS (HR=0.58), and lower LR (HR=0.70).
- No publication bias was detected.
Conclusions:
- NRT is likely beneficial for resectable RPS, improving OS and RFS.
- Further multicenter clinical trials are recommended to validate these findings.
